Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC.

TPS9112Background: Combination immunotherapy with nivolumab and ipilimumab has proven clinical activity in NSCLC. There is growing evidence to suggest that the tumor microenvironment (TME) may inte...